Weight loss medication originally intended for diabetics is taking the world by storm, with demand outweighing supply. On AM, Investment Analyst Dr Deborah Lambie discusses two companies with outstanding product results – Novo Nordisk (Wegovy) and Eli Elly (Mounjaro). She looks into the reasons why their effectiveness, and explains why it might be a while before New Zealanders can have ready access to the drugs.